Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
HP Version - Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
Optimise reading forHealth ProfessionalsPatients
Closed (no longer recruiting)Last updated: 2 February 2024
Clinical summaryEligibilityParticipating hospitalsSupport
This is a dose escalation and expansion study, in which eligible patients will receive oral MAX-10181 once or twice a day, with dose modifications based on set tolerability criteria. In part two of the study, eligible participants will receive oral MAX-10181 at a recommended dose, based on the outcomes of study part one.
This trial is treating patients with advanced solid cancers (excluding some types of blood cancer).
Multi-Cancer
18+
I
MaxiNovel
Use the hyperlinks, where available to access additional clinical trial information.
Maxinovel Pty., Ltd.
A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor
Haematological,Brain and spinal cord,Breast,CUP,Genitourinary,Gynaecological,Head and neck,Lower gastrointestinal tract,Lung,Sarcoma,Skin,Upper gastrointestinal tract
Share with email
Print this page
Download brochure
Clinical trials have complex eligibility criteria.
Ask your doctor if this trial could be right for you.
+ Show non-recruiting hospitals
Tell us if you find this trial availability is not accurate.Report inaccuracy
Speak with someone who has cancer clinical trial experience.
Learn more
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.